NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

Rhea-AI Summary

NeoGenomics (NASDAQ: NEO) will present three studies at the ESMO Congress 2024 in Barcelona, showcasing advancements in cancer diagnostics using ctDNA and NGS. Key findings include:

1. NGS testing for 19 drug-targetable fusions can identify up to 4x more patients for matched therapies compared to testing.

2. A large-scale study on ctDNA in early-stage NSCLC identifies high-risk patients who may benefit from aggressive treatment.

3. A Phase II trial evaluating ctDNA as a marker for treatment decisions in high-risk melanoma patients.

These studies highlight the potential of advanced molecular diagnostics to improve early cancer detection and personalized treatment strategies.

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization.

“Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics. “Collectively, our findings demonstrate the potential of advanced molecular diagnostics to detect cancer earlier, guide more personalized treatments, and ultimately improve patient outcomes worldwide.”

NeoGenomics’ poster presentations include:

• Real-World Analysis of Actionable Gene Fusions Identified by NGS and Correlation with IHC in 422 Patients from the Community (78P)
  • Presentation Date: Sunday, September 15, 2024
  • Results show that testing for 19 drug-targetable fusions can identify up to four times more patients for matched therapies compared to testing only for NTRK fusions or using IHC, suggesting that NGS testing for multiple fusions could greatly expand treatment options for cancer patients.
• ctDNA-Lung-Detect: Profiling of Non-Shedding ctDNA Early Stage Resected Non-Small Cell Lung Cancers (1236P)
  • Presentation Date: Saturday, September 14, 2024
  • This study represents one of the largest prospective cohorts of ctDNA assessments in early-stage non-small cell lung cancer (NSCLC), identifying patients at high risk of relapse who may benefit from more aggressive treatment.
• CLEAR-Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients with High-Risk Melanoma (226TiP)
  • Presentation Date: Sunday, September 15, 2024
  • This Phase II trial evaluated ctDNA as a marker to guide treatment decisions in high-risk melanoma patients. It compares the effectiveness of combining anti-LAG-3 with anti-PD-1 therapy versus anti-PD-1 inhibition alone.

For more details on NeoGenomics’ presentations, visit ESMO 2024.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240911211315/en/

Investor Contact

Kendra Sweeney

kendra.sweeney@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.

FAQ

What new data is NeoGenomics (NEO) presenting at ESMO 2024?

NeoGenomics is presenting three studies at ESMO 2024, focusing on ctDNA analysis and NGS for cancer diagnostics and personalized treatment. The studies cover actionable gene fusions in cancer patients, ctDNA profiling in early-stage NSCLC, and a trial using ctDNA to guide treatment in high-risk melanoma patients.

How does NGS testing improve treatment options according to NeoGenomics' (NEO) ESMO 2024 presentation?

NeoGenomics' study shows that NGS testing for 19 drug-targetable fusions can identify up to four times more patients for matched therapies compared to testing only for NTRK fusions or using IHC. This suggests that comprehensive NGS testing could significantly expand treatment options for cancer patients.

What did NeoGenomics' (NEO) ctDNA-Lung-Detect study at ESMO 2024 reveal?

The ctDNA-Lung-Detect study, presented at ESMO 2024, is one of the largest prospective cohorts of ctDNA assessments in early-stage non-small cell lung cancer (NSCLC). It identified patients at high risk of relapse who may benefit from more aggressive treatment, demonstrating the potential of ctDNA analysis in guiding treatment decisions.

What is the CLEAR-Me trial presented by NeoGenomics (NEO) at ESMO 2024?

The CLEAR-Me trial is a Phase II study presented by NeoGenomics at ESMO 2024. It evaluates ctDNA as a marker to guide treatment decisions in high-risk melanoma patients, comparing the effectiveness of combining anti-LAG-3 with anti-PD-1 therapy versus anti-PD-1 inhibition alone.

When and where is NeoGenomics (NEO) presenting its research at ESMO 2024?

NeoGenomics is presenting its research at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from September 13-17. The company's booth number is 438, and the poster presentations are scheduled for September 14 and 15, 2024.